Effects of dopaminergic agonists and antagonists on cerebellar guanosine-3′, 5′-monophosphate (cGMP)

doi:10.1016/0024-3205(78)90167-4

Life Sciences

Volume 23, Issue 5, 7 August 1978, Pages 533-536

https://doi.org/10.1016/0024-3205(78)90167-4 Get rights and content

Abstract

Apomorphine was found to cause an increase in cerebellar cGMP content. Bromocriptine, at a dose that caused stereotypies, neither elevated cGMP, nor blocked the apomorphine- induced rise in cGMP. The apomorphine-induced rise in cGMP was effectively blocked by haloperidol and some other neuroleptics, but not by sulpiride. These actions of the neuroleptics correlated with their ability to displace ³H-spiroperidol from striatal membranes, suggesting that dopamine receptor interactions were important in the cGMP changes noted. Based on the observation that haloperidol antagonized the increase induced by restraint, it is suggested that dopaminergic systems are involved in the reaction to stress.

References (9)

J.A. Ferrendelli et al.
Biochem. Biophys. Res. Comm.
(1972)
G. Biggio et al.
J. Pharmacol. Exp. Ther.
(1977)
S.W. Gumulka et al.
Naunyn-Schmiedeberg's Arch. Pharmacol.
(1976)
G. Biggio et al.
Nature
(1977)

There are more references available in the full text version of this article.

Cited by (8)

Cerebrospinal fluid cyclic guanosine 3'5' monophosphate levels in Parkinson's disease
1998, Journal of the Neurological Sciences
We measured CSF and plasma levels of cGMP in 22 patients with Parkinson's disease (PD) and in 28 age and sex-matched controls. PD patients had similar plasma cGMP levels than those of controls, although they showed a non-significant trend towards higher CSF cGMP levels (P=0.07). PD patients treated with levodopa showed significantly higher CSF cGMP levels than those not treated with this drug (P<0.01), and controls (P<0.01). However, treatment with dopamine agonists did not influence CSF cGMP levels. Plasma and CSF levels of cGMP did not correlate with age at onset, duration, and severity of PD. These results suggest that changes in the concentration of cGMP in CSF of patients with PD are not related with the disease, but rather with levodopa therapy.
Nitric oxide: A radical neurotransmitter in the central nervous system
1994, Progress in Neurobiology
Increase of cyclic GMP in cerebellum by methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate (DMCM)
1983, Brain Research
The intraperitoneal administration of DMCM (0.5–3 mg/kg) produced a dose-related increase in the content of cyclic GMP in the rat cerebellar cortex. The effect of DMCM on cyclic GMP was abolished by pretreatment with benzodiazepine receptor ligands, diazepam and Ro15-1788 and by the GABA agonist muscimol. The results suggest that DMCM increases cerebellar cyclic GMP content through a direct action on benzodiazepine receptors located in the cerebellar cortex. The interaction between DMCM and the GABAergic system associated with benzodiazepine receptors is discussed. Cerebellar cyclic GMP content can be used as a biochemical index to differentiate agonists and antagonists for benzodiazepine receptors.
Sudden decrease in cerebellar GABA binding induced by stress
1980, Pharmacological Research Communications
In the cerebellum of rats habituated to the handling maneuvers preceding killing the high affinity 3H-GABA receptor binding was found 80% higher than in cerebellum of naive rats. The increase of GABA binding resulted both from an increase in the number of available binding sites and in receptor affinity. The results suggest that stress due to the handling maneuvers preceding decapitation may influence GABA receptor binding in the central nervous system.
Brain nucleotides in naive and handling-habituated rats: differences in levels and drug-sensitivity
1980, Brain Research
Cerebellar pathology in schizophrenia-Cause or consequence?
1982, Neuroscience and Biobehavioral Reviews
Atrophy of the cerebellar vermal cortex has been reported to occur in 10% or more of patients with schizophrenia. Data from studies on experimental animals indicate that a functional relationship between the cerebellum and parts of the forebrain involved in emotion exists, and that the cerebellum may influence some types of behavior. Cerebellar abnormality in schizophrenic patients, although of uncertain cuase, could contribute to the symptomatology of the disease.

View all citing articles on Scopus

View full text

Effects of dopaminergic agonists and antagonists on cerebellar guanosine-3′, 5′-monophosphate (cGMP)

Abstract

Biochem. Biophys. Res. Comm.

J. Pharmacol. Exp. Ther.

Naunyn-Schmiedeberg's Arch. Pharmacol.

Nature